B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Senior Director - Regulatory Affairs CMC, Biologics

Regulatory & Quality (Life Sciences)Updated on Nov 10
Full-timeCambridge, MA, USA$242k - $313.5k

About the Job

Requirements

  • An advanced degree (PhD, MS, or PharmD) in biochemistry, molecular biology, pharmaceutical sciences, immunology, or a related biologics-relevant discipline is strongly preferred, or equivalent years of experience.
  • At least 12 years of CMC regulatory affairs experience in the pharmaceutical or biotechnology industry.
  • Deep expertise in biologics CMC regulatory strategy, including cell line development, upstream and downstream process development and validation, biophysical characterization, analytical method validation, and drug product formulation and fill-finish for parenteral biologics.
  • Extensive experience authoring and overseeing biologics CMC sections of global regulatory submissions, including INDs/CTAs, BLAs, MAAs, and post-approval supplements and variations in ICH CTD/eCTD format.
  • A track record of leading FDA and EMA biologics CMC Health Authority meetings, including BPD meetings, pre-BLA meetings, and strategic management of CMC deficiency letter responses.
  • Comprehensive knowledge of ICH Q8/Q9/Q10/Q11/Q12/Q13 guidelines, FDA biologics CMC guidance, including CDER and CBER guidance for therapeutic biologics, and EMA quality guidance applicable to monoclonal antibodies and other biological entities.
  • Experience managing biologics-specific CMC regulatory challenges, including comparability study strategy, reference standard lifecycle management, specification negotiation, and extended characterization regulatory justification.
  • Ability to lead and develop cross-functional teams in a fast-paced, resource-constrained biotechnology or pharmaceutical environment, fostering accountability, inclusion, and continuous learning.
  • Ability to influence without authority across organizational boundaries, drive alignment among senior stakeholders, and build consensus on complex regulatory or scientific priorities.
  • Experience navigating organizational ambiguity and change, defining structure, establishing priorities, and scaling functional capabilities in line with evolving corporate strategy.
  • Written and verbal communication skills to translate complex regulatory, scientific, or operational content for executive leadership, Health Authorities, and cross-functional partners.
  • Ability to prepare and deliver presentations, briefing documents, and strategic updates to cross-functional leadership teams, board-level stakeholders, and external regulatory agencies.
  • Active listening and ability to synthesize input from diverse perspectives into clear, actionable communications that build alignment and drive regulatory decision-making.

Responsibilities

  • Develop and lead CMC regulatory strategy for all biologics assets in the I&I portfolio from IND/CTA through BLA and MAA filing, including post-approval lifecycle management and labeling strategy for drug substance and drug product.
  • Author, review, and oversee biologics CMC sections of global regulatory submissions in ICH CTD format, including INDs/CTAs, BLAs, MAAs, supplements, and post-approval variations, ensuring scientific quality, completeness, and regulatory defensibility.
  • Serve as the primary regulatory authority and strategic partner for biologics Process Development, Upstream and Downstream Manufacturing Sciences, Analytical Development, Formulation, and Quality functions on CMC regulatory matters.
  • Lead Health Authority interactions on biologics CMC topics, including FDA Type B and Type C meetings (including BPD meetings), EMA Scientific Advice meetings, and written responses to CMC deficiency letters and information requests from global regulatory agencies.
  • Interpret FDA and EMA biologics CMC guidance and applicable ICH Q-series guidelines for large molecules, and advise development teams on process characterization, comparability, and control strategy regulatory acceptability.
  • Lead post-approval CMC change management strategy for biologics programs, including PACMP development, Prior Approval Supplements (PAS), CBE filings, and EU/global variation submissions related to manufacturing process changes, site changes, and analytical method updates.
  • Oversee regulatory aspects of biologics technology transfer activities, including biosimilar comparability assessments, new CMO site qualification, and regulatory filing strategies for site-to-site manufacturing transfers.
  • Provide regulatory guidance on biologics-specific CMC considerations, including cell line development, cell banking, upstream and downstream process validation, biophysical and functional characterization, and extended characterization strategies.
  • Contribute to regulatory due diligence evaluations of biologics licensing candidates or acquisition targets, assessing CMC regulatory risk, comparability study adequacy, and submission readiness.
  • Track CMC regulatory deliverables and submission timelines across biologics programs, identifying dependencies, risks, and upcoming milestones to keep cross-functional teams aligned and submission-ready.
  • Act as an integrated partner within the CMC team, attending technical meetings, engaging daily with Process Development, Analytical, Manufacturing Sciences, Drug Supply, and Quality colleagues, and translating regulatory strategy into practical guidance for CMC decisions and program progress.
  • Execute CMC regulatory responsibilities proactively by seeking information, building relationships across the CMC organization, taking ownership, and removing barriers through initiative.
  • Perform other duties and responsibilities as assigned.

About the Company

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Beeline Medicines focuses on precision therapies for autoimmune and inflammatory diseases, advancing a portfolio of in-licensed programs from Bristol Myers Squibb with strong backing from Bain Capital. Its lead, afimetoran, is an oral TLR7/8 inhibitor for lupus, with lomedeucitinib as an allosteric TYK2 inhibitor and two IND-stage biologics targeting IL-18 and IL-10 pathways to modulate immune signaling. The company differentiates itself by combining externally sourced programs with a leadership team experienced in drug development and commercialization, pursuing multiple mechanism-driven candidates rather than a single modality, supported by substantial early funding. Its goal is to move its clinical-stage therapies toward pivotal trials and bring targeted immune-modulating treatments to patients, beginning with completing Phase 2 for afimetoran in late 2026 and following with a pivotal program.

Company size
51-200
Company stage
Series A
Total funding
$426.3M
Headquarters
Stamford, CT
Founded
2025

Recently Posted Jobs

Explore more opportunities at Beeline Medicines

See more jobs